Advanced search
Publication Cover
Infectious Diseases Volume 47, 2015 - Issue 12
Submit an article Journal homepage
524
Views
61
CrossRef citations to date
0
Altmetric
BRIEF REPORT

Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency

Gregory L. HundemerFrom the Department of Medicine, Massachusetts General Hospital, Boston, MA, USA;Harvard Medical School, Boston, MA, USA
,
Meghan E. SiseDivision of Nephrology, Massachusetts General Hospital, Boston, MA, USA;Harvard Medical School, Boston, MA, USACorrespondence[email protected] [email protected]
,
Jessica WisockyGastrointestinal Unit, Massachusetts General Hospital, Boston, MA, USA;Harvard Medical School, Boston, MA, USA
,
Nneka UfereFrom the Department of Medicine, Massachusetts General Hospital, Boston, MA, USA;Harvard Medical School, Boston, MA, USA
,
Lawrence S. FriedmanDepartment of Medicine, Newton-Wellesley Hospital, Newton, MA, USA;Harvard Medical School, Boston, MA, USA;Tufts University School of Medicine, Boston, MA, USA
,
Kathleen E. CoreyGastrointestinal Unit, Massachusetts General Hospital, Boston, MA, USA;Harvard Medical School, Boston, MA, USA
&
Raymond T. ChungGastrointestinal Unit, Massachusetts General Hospital, Boston, MA, USA;Harvard Medical School, Boston, MA, USA
 show all
Pages 924-929 | Received 21 May 2015, Accepted 26 Jul 2015, Published online: 18 Aug 2015

References

  • Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013:368:34–44.
  • Gilead. Sofosbuvir for treatment of chronic hepatitis C infection. Antiviral drugs advisory committee meeting briefing document. 25 October 2013. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/antiviraldrugsadvisorycommittee/ucm371877.pdf
  • Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004;65: 2335–42.
  • Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat 2012;19: 601–7.
  • Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008;(109):S1–99.
  • Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis 2008;51:263–77.
  • Liu CH, Huang CF, Liu CJ, Dai CY, Liang CC, Huang JF, et al. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naïve patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med 2013;159:729–38.
  • Bhamidimarri KR, Gutierrez J, Grigorian A, Peyton A, Levy C, O’Brien C, et al. Urgent treatment with sofosbuvir based regimen for hepatitis C genotype 1 patients with severe renal insufficiency (GFR < 30mL/min). Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, November 7–11, 2014.
  • Saxena V, Koraishy FM, Sise M, Lim JK, Chung RT, Liapakis A, et al. LP08: safety and efficacy of sofosbuvir- containing regimens in hepatitis C infected patients with reduced renal function: real-world experience from HCV-target. J Hepatol 2015;62:S267.
  • Peck-Radosavlievic M, Boletis J, Besisik F, Ferraz ML, Alric L, Samuel D, et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clin Gastroenterol Hepatol 2011;9:242–8.
  • Tseng PL, Chen TC, Chien YS, Hung CH, Yen YH, Chang KC, et al. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts. Am J Kidney Dis 2013;62:789–95.
  • AASLD/IDSA HCVGuidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:932–54.
  • Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003;42:631–57.
  • Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia, H, Fretz C, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999;29:257–63.
  • Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, et al. LO1: safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-I study. J Hepatol 2015;62:S257.
  • Roth D, Nelson D, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, et al. LPO2: C-surfer: grazprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease. J Hepatol 2015;62:S263–4.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.